Prostate Cancer Reports

Volume 2 Number 2
 February 2014

Home > Prostate Cancer Reports > Volume 2 - Year 2014, Number 2, February 2014


Epidemiology and risk factors
Screening and early detection
Diagnosis and evaluation
Overall management and case reports
Integrative medicine
Prognosis and outcome


Catalá-López F, Suárez-Pinilla M, Suárez-Pinilla P, Valderas JM, Gómez-Beneyto M, Martinez S, Balanzá-Martínez V, Climent J, Valencia A, McGrath J, Crespo-Facorro B, Sanchez-Moreno J, Vieta E, Tabarés-Seisdedos R.
Inverse and direct cancer comorbidity in people with central nervous system disorders: a meta-analysis of cancer incidence in 577,013 participants of 50 observational studies.
Psychother Psychosom. 2014;83(2):89-105. doi: 10.1159/000356498. Epub 2014 Jan 22.
Abstract | Related citations

Sharp L, Donnelly D, Hegarty A, Carsin AE, Deady S, McCluskey N, Gavin A, Comber H.
Risk of Several Cancers is Higher in Urban Areas after Adjusting for Socioeconomic Status. Results from a Two-Country Population-Based Study of 18 Common Cancers.
J Urban Health. 2014 Jan 29. [Epub ahead of print]
Abstract | Related citations


Amaro A, Esposito AI, Gallina A, Nees M, Angelini G, Albini A, Pfeffer U.
Validation of proposed prostate cancer biomarkers with gene expression data: a long road to travel.
Cancer Metastasis Rev. 2014 Jan 30. [Epub ahead of print]
Abstract | Full text | Related citations

Turkbey B, Mena E, Shih J, Pinto PA, Merino MJ, Lindenberg ML, Bernardo M, McKinney YL, Adler S, Owenius R, Choyke PL, Kurdziel KA.
Localized Prostate Cancer Detection with (18)F FACBC PET/CT: Comparison with MR Imaging and Histopathologic Analysis.
Radiology. 2014 Mar;270(3):849-56. doi: 10.1148/radiol.13130240. Epub 2013 Nov 8.
Abstract | Related citations


Caras RJ, Sterbis JR.
Prostate cancer nomograms: a review of their use in cancer detection and treatment.
Curr Urol Rep. 2014 Mar;15(3):391. doi: 10.1007/s11934-013-0391-0.
Abstract | Related citations


Calabria F, Rubello D, Schillaci O.
The optimal timing to perform 18F/11C-choline PET/CT in patients with suspicion of relapse of prostate cancer: trigger PSA versus PSA velocity and PSA doubling time.
Int J Biol Markers. 2014 Jan 22:0. doi: 10.5301/jbm.5000068. [Epub ahead of print]
Abstract | Related citations

Kitajima K, Murphy RC, Nathan MA, Froemming AT, Hagen CE, Takahashi N, Kawashima A.
Detection of Recurrent Prostate Cancer After Radical Prostatectomy: Comparison of 11C-Choline PET/CT with Pelvic Multiparametric MR Imaging with Endorectal Coil.
J Nucl Med. 2014 Feb;55(2):223-32. doi: 10.2967/jnumed.113.123018. Epub 2014 Jan 16.J Nucl Med. 2014 Feb;55(2):223-32. doi: 10.2967/jnumed.113.123018. Epub 2014 Jan 16.
Abstract | Related citations

Kupka da Silva R, Dall'Oglio MF, Sant'Ana AC, Pontes J Jr, Srougi M.
Can single positive core prostate cancer at biopsy be considered a low-risk disease after radical prostatectomy?
Int Braz J Urol. 2013 Nov-Dec;39(6):800-7. doi: 10.1590/S1677-5538.IBJU.2013.06.05.
Abstract | Full text | Related citations

Takahashi M, Horiguchi A, Tasaki S, Kuroda K, Sato A, Asakuma J, Seguchi K, Hayakawa M, Ito K, Asano T, Tamura C, Shinmoto H.
[The diagnostic value of pre-biopsy magnetic resonance imaging for precise detection of clinically localized prostate cancer compared to post-biopsy setting].
Hinyokika Kiyo. 2013 Dec;59(12):769-73.
Abstract | Related citations



Knoedler JJ, Karnes RJ, Thompson RH, Rangel LJ, Bergstralh EJ, Boorjian SA.
The association of tumor volume with mortality following radical prostatectomy.
Prostate Cancer Prostatic Dis. 2014 Jan 28. doi: 10.1038/pcan.2013.61. [Epub ahead of print]
Abstract | Related citations

Ost P, Decaestecker K, Lambert B, Fonteyne V, Delrue L, Lumen N, Ameye F, De Meerleer G.
Prognostic factors influencing prostate cancer-specific survival in non-castrate patients with metastatic prostate cancer.
Prostate. 2014 Feb;74(3):297-305. doi: 10.1002/pros.22750.
Abstract | Related citations

Schupp CW, Press DJ, Gomez SL.
Immigration factors and prostate cancer survival among Hispanic men in California: Does neighborhood matter?
Cancer. 2014 Jan 29. doi: 10.1002/cncr.28587. [Epub ahead of print]
Abstract | Related citations



Graham J, Kirkbride P, Cann K, Hasler E, Prettyjohns M.
Prostate cancer: summary of updated NICE guidance.
BMJ. 2014 Jan 8;348:f7524. doi: 10.1136/bmj.f7524.
Abstract | Related citations


Xu EX.
Highlights in focus issue on prostate cancer.
Chin J Cancer Res. 2013 Dec;25(6):784-5. doi: 10.3978/j.issn.1000-9604.2013.12.10.
Abstract | Full text | Related citations

Case reports

Iwamura H, Hatakeyama S, Tanaka Y, Tanaka T, Tokui N, Yamamoto H, Imai A, Yoneyama T, Hashimoto Y, Koie T, Yoshikawa K, Ohyama C.
A case of metastatic cancer with markedly elevated PSA level that was not detected by repeat prostate biopsy.
BMC Res Notes. 2014 Jan 29;7:64. doi: 10.1186/1756-0500-7-64.
Abstract | Full text | Related citations


Overviews on treatment options

Ghavamian R.
Prostate Cancer Treatment Protocols
Medscape, Jan 3, 2014
Abstract | Full text

Janetschek G, Hruby S.
Prostate cancer: How to manage prostate cancer with lymph node metastases?
Nat Rev Urol. 2014 Mar;11(3):137-8. doi: 10.1038/nrurol.2013.321. Epub 2014 Jan 21.
Abstract | Related citations

Schweizer MT, Drake CG.
Immunotherapy for prostate cancer: recent developments and future challenges.
Cancer Metastasis Rev. 2014 Jan 30. [Epub ahead of print]
Abstract | Related citations

Special topics


Kawada T.
Meta-analysis procedure for the effect of statin on the recurrence of prostate cancer.
Ann Oncol. 2014 Feb;25(2):543. doi: 10.1093/annonc/mdt563. Epub 2014 Jan 12.
Abstract | Full text | Related citations

Park H, Schoenfeld J, Mucci L.
Reply to 'Meta-analysis procedure for the effect of statin on the recurrence of prostate cancer' by T. Kawada.
Ann Oncol. 2014 Feb;25(2):543-4. doi: 10.1093/annonc/mdt565. Epub 2014 Jan 12.
Abstract | Full text | Related citations

First-line treatment

Localized PCa

Bernstein MB, Ohri N, Hodge JW, Garg M, Bodner W, Kalnicki S, Dicker AP, Guha C.
Prostate-specific antigen bounce predicts for a favorable prognosis following brachytherapy: a meta-analysis.
J Contemp Brachytherapy. 2013 Dec;5(4):210-4. doi: 10.5114/jcb.2013.38875. Epub 2013 Nov 14.
Abstract | Full text | Related citations

Guttilla A, Bortolus R, Giannarini G, Ghadjar P, Zattoni F, Gnech M, Palumbo V, Valent F, Garbeglio A, Zattoni F.
Multimodal treatment for high-risk prostate cancer with high-dose intensity-modulated radiation therapy preceded or not by radical prostatectomy, concurrent intensified-dose docetaxel and long-term androgen deprivation therapy: results of a prospective phase II trial.
Radiat Oncol. 2014 Jan 14;9:24. doi: 10.1186/1748-717X-9-24.
Abstract | Full text | Related citations

Lazzeri M, Losa A, Buffi N, Lughezzani G, Fossati N, Abrate A, Larcher A, Lista G, Mistretta A, Guazzoni G.
[Focal therapy and prostate cancer].
Urologia. 2013 Sep-Dec;80(4):283-9. doi: 10.5301/RU.2013.11667. Epub 2013 Dec 9. Italian.
Abstract | Related citations

Mearini L, Nunzi E, Bini V, Lepri L, Bruno R, Porena M.
[Radical prostatectomy in high-risk prostate cancer: incidence of specimen-confined disease (pT2-pT3a N0R0) and outcomes.]
Urologia. 2013 Nov 29;0(0):0. doi: 10.5301/urologia.5000030. [Epub ahead of print] Italian.
Abstract | Related citations

Polkinghorn WR, Zelefsky MJ.
Improving outcomes in high-risk prostate cancer with radiotherapy.
Rep Pract Oncol Radiother. 2013 Nov 11;18(6):333-337. eCollection 2013.
Abstract | Related citations

Rodrigues G, Yao X, Loblaw DA, Brundage M, Chin JL.
Low-dose rate brachytherapy for patients with low- or intermediate-risk prostate cancer: A systematic review.
Can Urol Assoc J. 2013 Nov;7(11-12):463-470.
Abstract | Full text | Tables | Related citations

Taira AV, Merrick GS, Butler WM, Galbreath RW, Fiano R, Wallner KE, Adamovich E.
Time to failure after definitive therapy for prostate cancer: implications for importance of aggressive local treatment.
J Contemp Brachytherapy. 2013 Dec;5(4):215-21. doi: 10.5114/jcb.2013.39210. Epub 2013 Dec 3.
Abstract | Full text | Related citations

Vu CC, Haas JA, Katz AE, Witten MR.
Prostate-specific antigen bounce following stereotactic body radiation therapy for prostate cancer.
Front Oncol. 2014 Jan 28;4:8. doi: 10.3389/fonc.2014.00008. eCollection 2014.
Abstract | Full text | Related citations

Locally advanced PCa

Crehange G, Izaguirre A, Weinberg V, Hsu CC, Gottschalk AR, Hsu IC, Shinohara K, Carroll P, Roach M 3rd.
Long-term Outcomes Following Radiation Therapy For Prostate Cancer Patients With Lymph Node Metastases at Diagnosis Treated With and Without Surgery.
Am J Clin Oncol. 2014 Jan 16. [Epub ahead of print]
Abstract | Related citations

Sato YT, Fukuhara H, Suzuki M, Fujimura T, Nakagawa T, Nishimatsu H, Kume H, Morikawa T, Fukayama M, Homma Y.
Long-term results of radical prostatectomy with immediate adjuvant androgen deprivation therapy for pT3N0 prostate cancer.
BMC Urol. 2014 Jan 29;14:13. doi: 10.1186/1471-2490-14-13.
Abstract | Full text | Related citations


Localized PCa

Gastaldi E, Gallo F, Chiono L, Giberti C.
Salvage low-dose-rate brachytherapy for prostate cancer local recurrence after radical prostatectomy: our first three patients.
Urologia. 2013 Nov 28;0(0):0. doi: 10.5301/urologia.5000034. [Epub ahead of print]
Abstract | Related citations

Advanced PCa

Ranasinghe WK, Sengupta S, Williams S, Chang M, Shulkes A, Bolton DM, Baldwin G, Patel O.
The effects of nonspecific HIF1α inhibitors on development of castrate resistance and metastases in prostate cancer.
Cancer Med. 2014 Jan 27. doi: 10.1002/cam4.189. [Epub ahead of print]
Abstract | Full text | Related citations

Smith MR, Halabi S, Ryan CJ, Hussain A, Vogelzang N, Stadler W, Hauke RJ, Monk JP, Saylor P, Bhoopalam N, Saad F, Sanford B, Kelly WK, Morris M, Small EJ.
Randomized Controlled Trial of Early Zoledronic Acid in Men With Castration-Sensitive Prostate Cancer and Bone Metastases: Results of CALGB 90202 (Alliance).
J Clin Oncol. 2014 Mar 3. [Epub ahead of print]
Abstract | Related citations

Brooks M.,
No Benefit to Earlier Use of Bone Drug in Prostate Cancer., Medscape, 2014 Mar 06., Abstract | Full text
Johnson K.,
Zoledronic Acid Fails to Halt Metastasis in Prostate Cancer., Medscape, 2014 Mar 26., Abstract | Full text

Sternberg CN, de Bono JS, Chi KN, Fizazi K, Mulders P, Cerbone L, Hirmand M, Forer D, Scher HI.
Improved outcomes in elderly patients with metastatic castration-resistant prostate cancer treated with the androgen receptor inhibitor enzalutamide: results from the phase III AFFIRM trial.
Ann Oncol. 2014 Feb;25(2):429-34. doi: 10.1093/annonc/mdt571.
Abstract | Related citations

Culp SH, Schellhammer PF, Williams MB.
Might Men Diagnosed with Metastatic Prostate Cancer Benefit from Definitive Treatment of the Primary Tumor? A SEER-Based Study.
Eur Urol. 2013 Nov 20. pii: S0302-2838(13)01209-8. doi: 10.1016/j.eururo.2013.11.012. [Epub ahead of print]
Abstract | Related citations

Treatment comparison

Locally advanced PCa

Gandaglia G, Sun M, Trinh QD, Becker A, Schiffmann J, Hu JC, Briganti A, Montorsi F, Perrotte P, Karakiewicz PI, Abdollah F.
Survival benefit of definitive therapy in patients with clinically advanced prostate cancer: estimations of the number needed to treat based on competing-risks analysis.
BJU Int. 2014 Jan 27. doi: 10.1111/bju.12645. [Epub ahead of print]
Abstract | Related citations

Botrel TE, Clark O, dos Reis RB, Pompeo AC, Ferreira U, Sadi MV, Bretas FF.
Intermittent versus continuous androgen deprivation for locally advanced, recurrent or metastatic prostate cancer: a systematic review and meta-analysis.
BMC Urol. 2014 Jan 25;14:9. doi: 10.1186/1471-2490-14-9.
Abstract | Full text | Related citations


El-Saghire H, Vandevoorde C, Ost P, Monsieurs P, Michaux A, De Meerleer G, Baatout S, Thierens H.
Intensity modulated radiotherapy induces pro-inflammatory and pro-survival responses in prostate cancer patients.
Int J Oncol. 2014 Apr;44(4):1073-83. doi: 10.3892/ijo.2014.2260. Epub 2014 Jan 17.
Abstract | Full text | Related citations

Nam RK, Cheung P, Herschorn S, Saskin R, Su J, Klotz LH, Chang M, Kulkarni GS, Lee Y, Kodama RT, Narod SA.
Incidence of complications other than urinary incontinence or erectile dysfunction after radical prostatectomy or radiotherapy for prostate cancer: a population-based cohort study.
Lancet Oncol. 2014 Feb;15(2):223-31. doi: 10.1016/S1470-2045(13)70606-5. Epub 2014 Jan 17.
Abstract | Related citations


Hu MB, Xu H, Bai PD, Jiang HW, Ding Q.
Obesity has multifaceted impact on biochemical recurrence of prostate cancer: a dose-response meta-analysis of 36,927 patients.
Med Oncol. 2014 Feb;31(2):829. doi: 10.1007/s12032-013-0829-8. Epub 2014 Jan 5.
Abstract | Related citations

Sundi D, Wang V, Pierorazio PM, Han M, Partin AW, Tran PT, Ross AE, Bivalacqua TJ.
Identification of men with the highest risk of early disease recurrence after radical prostatectomy.
Prostate. 2014 Jan 22. doi: 10.1002/pros.22780. [Epub ahead of print]
Abstract | Related citations


Bikle DD.
Vitamin D and cancer: the promise not yet fulfilled.
Endocrine. 2014 Jan 9. [Epub ahead of print]
Abstract | Related citations

Der T, Bailey BA, Youssef D, Manning T, Grant WB, Peiris AN.
Vitamin D and prostate cancer survival in veterans.
Mil Med. 2014 Jan;179(1):81-4. doi: 10.7205/MILMED-D-12-00540.
Abstract | Full text | Related citations

Printz C.
Coffee consumption linked to a reduction in prostate cancer recurrence.
Cancer. 2014 Jan 15;120(2):157. doi: 10.1002/cncr.28542.
Abstract | Full text | Related citations

Wang Y, Zhang S, Iqbal S, Chen Z, Wang X, Wang YA, Liu D, Bai K, Ritenour C, Kucuk O, Wu D.
Pomegranate extract inhibits the bone metastatic growth of human prostate cancer cells and enhances the in vivo efficacy of docetaxel chemotherapy.
Prostate. 2013 Dec 23. doi: 10.1002/pros.22769. [Epub ahead of print]
Abstract | Related citations

Zu K, Mucci L, Rosner BA, Clinton SK, Loda M, Stampfer MJ, Giovannucci E.
Dietary lycopene, angiogenesis, and prostate cancer: a prospective study in the prostate-specific antigen era.
J Natl Cancer Inst. 2014 Feb;106(2):djt430. doi: 10.1093/jnci/djt430. Epub 2014 Jan 24.
Abstract | Related citations